Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03665077 · ClinicalTrials.gov registry record · NA
Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome
A NA study of Breast Cancer and Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS), sponsored by University of Arizona.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03665077: Completed NA study of Breast Cancer and Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS), sponsored by University of Arizona.
NCT03665077 is a NA study of Breast Cancer and Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS) that has completed, run by University of Arizona. The registered enrollment target is 28 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03665077, a NA study of Breast Cancer and Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS), has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot trial to evaluate for blood and imaging biomarkers in patients with breast cancer scheduled to start adjuvant hormonal therapy.
Primary Outcome
Change Oxylipin levels at Baseline, Three and Six Months
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Initial blood draw
- DIAGNOSTIC_TEST Initial SWE ultrasound
- DIAGNOSTIC_TEST Blood draw at three months
- DIAGNOSTIC_TEST Blood draw at six months
- DIAGNOSTIC_TEST SWE ultrasound at six months
Study Locations (1)
Arizona
- University of Arizona Cancer Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-02-28 |
| Est. Completion | 2022-06-15 |
| Phase | NA |
What the finished NCT03665077 record still lists
NCT03665077 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Initial blood draw is the first listed.
NCT03665077 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT03665077 about?
NCT03665077 is a clinical study titled "Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome". This is a pilot trial to evaluate for blood and imaging biomarkers in patients with breast cancer scheduled to start adjuvant hormonal therapy.
What is the current status of trial NCT03665077?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2018-02-28. Estimated completion is 2022-06-15.
What conditions does trial NCT03665077 study?
This clinical trial studies the following conditions: Breast Cancer, Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS).
What interventions are being tested in trial NCT03665077?
The interventions under investigation include: Initial blood draw (DIAGNOSTIC_TEST), Initial SWE ultrasound (DIAGNOSTIC_TEST), Blood draw at three months (DIAGNOSTIC_TEST), Blood draw at six months (DIAGNOSTIC_TEST), SWE ultrasound at six months (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03665077?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03665077 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03665077's enrollment target sits among peer trials
28 1005th of 1224 higher than 207 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI